Three Houston Firms Get Texas Emerging Technology Funding

Three Houston companies are sharing a total of $2.9M in funding from the Texas Emerging Technology Fund (TETF), according to the Gulf Coast Regional Center of Innovation and Commercialization. According to the GCRCIC, AuricX Pharmaceuticals has received $250,000 in a Pre-Seed Commercialization Award, Blue Box Health has received $250,000 in another Pre-Seed Commercialization Award, and Oncolix has received $2.4M in a Commercialization Award. AuricX is developing anti-infectives targeted at treating Methicillin-resistant Staphylococcus aureus (MRSA) and other infections; Blue Box Health is developing a biosensor aimed at early detection and mitigation of heart disease; Oncolix, which relocated here in 2009, has developed a non-chemotherapy drug for treating ovarian cancer, which is currently going into clinical trails with assistance from MD Anderson.